1174 related articles for article (PubMed ID: 19623034)
21. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
22. P16(INK4a) protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: diagnostic and clinical considerations.
Caponio MA; Addati T; Popescu O; Petroni S; Rubini V; Centrone M; Trojano G; Simone G
Cancer Biomark; 2014; 14(2-3):169-75. PubMed ID: 24878818
[TBL] [Abstract][Full Text] [Related]
23. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Han CP; Lee MY; Kok LF; Ruan A; Wu TS; Cheng YW; Tyan YS; Lin CY
Int J Gynecol Pathol; 2009 Sep; 28(5):489-96. PubMed ID: 19696622
[TBL] [Abstract][Full Text] [Related]
24. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
Salvesen HB; Das S; Akslen LA
Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
[TBL] [Abstract][Full Text] [Related]
25. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
26. p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas.
Santos M; Landolfi S; Olivella A; Lloveras B; Klaustermeier J; Suárez H; Alòs L; Puig-Tintoré LM; Campo E; Ordi J
Am J Surg Pathol; 2006 Nov; 30(11):1347-56. PubMed ID: 17063073
[TBL] [Abstract][Full Text] [Related]
27. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms.
Ronnett BM; Yemelyanova AV; Vang R; Gilks CB; Miller D; Gravitt PE; Kurman RJ
Am J Surg Pathol; 2008 Dec; 32(12):1835-53. PubMed ID: 18813124
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
[TBL] [Abstract][Full Text] [Related]
29. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
[TBL] [Abstract][Full Text] [Related]
30. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
[TBL] [Abstract][Full Text] [Related]
31. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
Kong CS; Beck AH; Longacre TA
Am J Surg Pathol; 2010 Jul; 34(7):915-26. PubMed ID: 20534993
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
33. p16, p14, p53, and cyclin D1 expression and HPV analysis in small cell carcinomas of the uterine cervix.
Horn LC; Lindner K; Szepankiewicz G; Edelmann J; Hentschel B; Tannapfel A; Bilek K; Liebert UG; Richter CE; Einenkel J; Leo C
Int J Gynecol Pathol; 2006 Apr; 25(2):182-6. PubMed ID: 16633070
[TBL] [Abstract][Full Text] [Related]
34. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
36. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.
Reid-Nicholson M; Iyengar P; Hummer AJ; Linkov I; Asher M; Soslow RA
Mod Pathol; 2006 Aug; 19(8):1091-100. PubMed ID: 16648864
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors.
Buza N; Tavassoli FA
Int J Gynecol Pathol; 2009 Nov; 28(6):514-21. PubMed ID: 19851197
[TBL] [Abstract][Full Text] [Related]
38. [Serous adenocarcinoma of the uterus: criteria of morphological diagnosis and immunohistochemistry].
Vasil'eva EV; Belianin VL
Arkh Patol; 2005; 67(2):25-7. PubMed ID: 15938115
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical expression of 14-3-3 sigma protein in various histological subtypes of uterine cervical cancers.
Sano T; Shimooka H; Weixa P; Segawa A; Jian Z; Motegi A; Nakayama H; Oyama T; Nakajima T
Pathol Int; 2004 Oct; 54(10):743-50. PubMed ID: 15482563
[TBL] [Abstract][Full Text] [Related]
40. Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA.
Lu DW; El-Mofty SK; Wang HL
Mod Pathol; 2003 Jul; 16(7):692-9. PubMed ID: 12861066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]